Item 8.01 - Other Events.
Study 311 is a phase 1 pharmacokinetic study in fasted healthy adult subjects who will be taking 2, 5 and 9 tablet doses. Study 311 is targeted to have 20 subjects complete all doses which will be administered in crossover fashion over a 4 week dosing period, with one week washout between doses. All subjects will receive an intravenous naloxone blockade during drug administration to negate the pharmacologic effects of the opioid hydrocodone. The Company expects to compare the results from the LTX-03 doses to the known, well-characterized pharmacokinetic results for hydrocodone and acetaminophen from the published literature with the intent to demonstrate lower levels of hydrocodone exposure for LTX-03 compared to the currently marketed comparator product as increasing number of tablets are ingested. The acetaminophen active ingredient is not incorporated into the LIMITx technology in the LTX-03 tablet and is not expected to be substantially different from the comparator product.
LTX-03 (hydrocodone with acetaminophen)
Recent reports suggest growing numbers of legitimate pain patients are going
undertreated as they can no longer find doctors willing to treat them due to new
prescribing guidelines associated with the opioid epidemic. Suicide is
increasingly seen as the only remedy for some of these patients through opioid
overdose. Our goal with LIMITx is to develop a treatment for effective pain
relief at a one or two tablet dose while providing overdose protection by
limiting high peak levels of drug in the bloodstream (Cmax) that can lead to
respiratory depression and death when more than the recommended dose is
ingested. LIMITx works by neutralizing stomach acid with buffering ingredients
as increasing numbers of tablets are swallowed thereby reducing the stomach acid
available to cause the release and subsequent systemic absorption of the active
ingredient from micro-particles contained in the LIMITx tablets. In a human
clinical study, formulations of LTX-03 demonstrated, under fasted conditions,
analgesic levels of hydrocodone in the blood when taken at a recommended one or
two tablet dose but reduced the maximum blood level (Cmax) up to 34% when
subjects were exposed to higher buffer ingredient levels. Hydrocodone with
acetaminophen remains the single largest prescribed opioid in the
2 Forward-Looking Statements
Statements in this Current Report constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.
Forward-looking statements may include, but are not limited to:
• our ability to fund or obtain funding for our continuing operations, including
the development of our products utilizing our LIMITx and IMPEDE technologies;
• whether we will receive FDA acceptance for an NDA for LTX-03 by the target
date;
• whether our licensees will terminate the license prior to commercialization;
• the expected results of clinical studies relating to LTX-03 or any successor
product candidate, the date by which such studies will complete and the results will be available and whether any product candidate will ultimately receive FDA approval;
• the ability of LTX-03 single tablets to achieve bioequivalence or to
demonstrate efficacy in a clinical study;
• whether our licensing partners will develop any additional products and utilize
Acura for such development;
• whether LIMITx will retard the release of opioid active ingredients as dose
levels increase;
• whether the extent to which products formulated with the LIMITx technology
mitigate respiratory depression risk will be determined sufficient by the FDA;
• our and our licensee's ability to successfully launch and commercialize our
products and technologies;
• our and our licensee's ability to obtain necessary regulatory approvals and
commercialize products utilizing our technologies;
• the market acceptance of, timing of commercial launch and competitive
environment for any of our products;
• our ability to develop and enter into additional license agreements for our
product candidates using our technologies;
• the ability to avoid infringement of patents, trademarks and other proprietary
rights of third parties;
• the ability of our patents to protect our products from generic competition and
our ability to protect and enforce our patent rights in any paragraph IV patent
infringement litigation;
• the adequacy of the development program for our product candidates, including
whether additional clinical studies will be required to support an NDA and FDA
approval of our product candidates;
• changes in regulatory requirements;
• adverse safety findings relating to our commercialized products or product
candidates in development;
• whether or when we are able to obtain FDA approval of labeling for our product
candidates for the proposed indications and whether we will be able to promote
the features of our technologies; and
• whether our product candidates will ultimately perform as intended in
commercial settings.
In some cases, you can identify forward- looking statements by terms such as
"may," "will", "should," "could," "would," "expects," "plans," "anticipates,"
"believes," "estimates," "indicates", "projects," "predicts," "potential" and
similar expressions intended to identify forward-looking statements. These
statements reflect our current views with respect to future events and are based
on assumptions and subject to risks and uncertainties. Given these
uncertainties, you should not place undue reliance on these forward-looking
statements. We discuss many of these risks in greater detail in our filings with
the
3
© Edgar Online, source